10 recruiting, 6 completed, 3 not yet recruiting, 3 unknown. 9 Phase 2, 4 Phase 3, 3 Not applicable, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 3, Recruiting 3, Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 3 | 4 | Unknown 2, Completed 1, Not yet recruiting 1 |
| Not applicable | 3 | Recruiting 3 |
| Phase 4 | 2 | Completed 2 |
Follow Minimal Change Disease: new trials by email Literature Review of Minimal Change Disease trials Research Report on Minimal Change Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change Disease Sibeprenlimab - Primary Membranous Nephropathy, Minimal Change Disease | Phase 2 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 20 | 2026-12-15 | 2026-10-06 |
| An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases ManNAc - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | National Human Genome Research Institute (NHGRI) | 30 | 2026-11-01 | 2026-10-27 |
| Study of WAL0921 in Patients With Glomerular Kidney Diseases WAL0921, Placebo - Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis | Phase 2 | Recruiting | Walden Biosciences | 96 | 2024-07-02 | 2026-08-03 |
| Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD Supportive care+Prednisone, Supportive care+Tacrolimus+Ripertamab, Supportive care+Ripertamab - Minimal Change Disease | Phase 3 | Not yet recruiting | Air Force Military Medical University, China | 81 | 2024-05-01 | 2024-05-08 |
| Circulating Factors in Nephrotic Syndrome Observation - Nephrotic Syndrome, Membranous Nephropathy | Not yet recruiting | Iain Bressendorff | 104 | 2024-04-01 | 2024-03-19 | |
| taVNS for FRNS in Children Transcutaneous auricular vagus nerve stimulation, Sham device - Nephrotic Syndrome in Children, Minimal Change Disease | Not applicable | Recruiting | Northwell Health | 30 | 2023-01-05 | 2026-04-15 |
| Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease Biospecimen collection, Data collection - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Recruiting | University of Michigan | 300 | 2022-12-08 | 2026-04-29 | |
| A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS) trascutaneous auricular vagus nerve stimulation, Sham device - Nephrotic Syndrome in Children, Minimal Change Disease | Not applicable | Recruiting | Northwell Health | 10 | 2022-09-19 | 2026-04-17 |
| Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) VB119 - Minimal Change Disease, Focal Segmental Glomerulosclerosis | Phase 2 | Terminated | Tenet Medicines | 1 | 2022-05-03 | 2024-04-22 |
| NEPTUNE Match Study Communication - Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis | Not applicable | Recruiting | University of Michigan | 375 | 2022-05-02 | 2026-06-10 |
| Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome. Interview - Fluid Overload, Glomerulosclerosis, Focal Segmental | Recruiting | University of Michigan | 150 | 2022-04-18 | 2025-12-22 | |
| Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases Sparsentan - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | Travere Therapeutics, Inc. | 67 | 2021-08-12 | 2026-05-12 |
| A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN) FSGS/TR-MCD, Diabetic Nephropathy (DN) - Glomerulosclerosis, Focal Segmental, Minimal Change Disease | Terminated | Goldfinch Bio, Inc. | 20 | 2019-12-20 | 2021-07-20 | |
| Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease adalimumab - FSGS, MCD | Phase 2 | Completed | University of Michigan | 7 | 2019-10-02 | 2024-10-30 |
| Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease Focal Segmental Glomerulosclerosis, Minimal Change Disease | Completed | Istanbul University | 25 | 2019-09-01 | 2020-12-01 | |
| KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis Kidney Biopsy - Glomerular Disease, Minimal Change Disease | Recruiting | Seoul National University Hospital | 3000 | 2019-05-01 | 2020-02-12 | |
| Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome Rituximab, Prednisone - Idiopathic Nephrotic Syndrome, Minimal Change Disease | Phase 3 | Unknown | Radboud University Medical Center | 40 | 2018-08-22 | 2018-08-27 |
| Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy Prednisolone, Alfacalcidol - Minimal Change Disease, Nephrotic Syndrome | Phase 4 | Completed | University of Aarhus | 71 | 2018-05-01 | 2025-01-24 |
| The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry) Biosampling - Glomerulosclerosis, Focal Segmental, Minimal Change Disease | Recruiting | Prof. Dr. Paul Brinkkoetter | 500 | 2018-04-01 | 2025-09-17 | |
| Diagnostic Value of Linked Color Imaging for Minimal Change Esophagitis in Nonerosive Reflux Esophagitis and GERD Gastroesophageal Reflux Disease, Minimal Change Disease | Unknown | Affiliated Hospital to Academy of Military Medical Sciences | 90 | 2017-01-15 | 2017-09-19 |
Showing 20 of 24. Sign in to see all of them.
Nephrosis, Lipoid (24) · Glomerulosclerosis, Focal Segmental (17) · Nephrotic Syndrome (7) · Macular dystrophy, corneal type 1 (6) · Glomerulonephritis, Membranous (5) · Glomerulonephritis, IGA (3) · Kidney Diseases (3) · Diabetic Nephropathies (2) · Nephritis, Hereditary (2) · Disease (1) · Edema (1) · Gastroesophageal Reflux (1) · IgA Vasculitis (1) · Lupus Nephritis (1) · Non-Erosive Reflux Disease (1)
Female Urogenital Diseases (24) · Female Urogenital Diseases and Pregnancy Complications (24) · Male Urogenital Diseases (24) · Nephrosis (24) · Urogenital Diseases (24) · Urologic Diseases (24) · Kidney Diseases (21) · Glomerulonephritis (19) · Nephritis (19) · Autoimmune Diseases (7) · Immune System Diseases (7) · Pathological Conditions, Signs and Symptoms (4) · Connective Tissue Diseases (3) · Pathologic Processes (3) · Signs and Symptoms (3)
Prednisolone (3) · Prednisone (2) · Tacrolimus (2) · Abatacept (1) · Adalimumab (1) · Control Groups (1) · Data Collection (1) · Glucose (1) · Interviews as Topic (1) · N-acetylmannosamine (1) · Observation (1) · Rituximab (1) · Saline Solution (1) · Valproic Acid (1) · Water (1)
University of Michigan (4) · Northwell Health (2) · Seoul National University Hospital (2) · Affiliated Hospital to Academy of Military Medical Sciences (1) · Air Force Military Medical University, China (1) · Bristol-Myers Squibb (1) · Goldfinch Bio, Inc. (1) · Iain Bressendorff (1) · Imperial College Healthcare NHS Trust (1) · Istanbul University (1) · National Human Genome Research Institute (NHGRI) (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Prof. Dr. Paul Brinkkoetter (1) · Radboud University Medical Center (1) · Tenet Medicines (1)
United States (12) · South Korea (3) · United Kingdom (3) · Germany (2) · Netherlands (2) · Australia (1) · Belgium (1) · China (1) · Denmark (1) · India (1) · Italy (1) · Malaysia (1) · Poland (1) · Spain (1) · Sri Lanka (1)
Dong Ki Kim, MD, PhD (1) · Eloise Salmon, M.D. (1) · Eloise Salmon, MD (1) · Halil Yazici, MD (1) · Jack F Wetzels, MD, PhD (1) · Jeroen K Deegens, MD,PhD (1) · John Peipert, Ph.D. (1) · Matthias Kretzler, MD (1) · Megan Griffith, MBChBPhDFRCP (1) · Paul T Brinkkoetter, MD (1) · Per Ivarsen (1) · Peter Janssens, MD (1) · Radko Komers, MD, PhD (1)
PMID 38724717, PMID 35230699, PMID 35224732, PMID 17681166, PMID 22156539, PMID 25628366, PMID 30302374, PMID 32842999, PMID 34247632, PMID 37117201, PMID 39808779, PMID 40337980, PMID 40938675, PMID 41630898, PMID 41905593, PMID 42384439
R01DK131091 (2), 2009 (1), 2015 (1), R01DK141114 (1), U54DK083912 (1)